Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rujietai
- Development stage
- Phase 4
- Lead developer
- Yiling Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rujietai is a pharmaceutical capsule developed for the treatment of hyperplasia of mammary glands, also known as mammary gland hyperplasia. It has been approved for use in China and is primarily indicated for this condition. The drug was initially developed by Hengshui Yiling Pharmaceutical and later obtained marketing rights through Shijiazhuang Yiling Pharmaceutical. Its mechanism of action and specific active ingredients are not detailed in the available sources, but it is used therapeutically to address benign proliferative disorders of breast tissue[1][2][3].
- Brand names
- RujietaiRujietai Capsule
Beyond the preview
Go deeper on Rujietai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rujietai.